A study of clinical trials found no evidence of bias in the reporting of clinical trials supported by pharmaceutical companies compared with studies that had other funding sources.
A meta-analysis of randomized controlled trials found that there are significant risks for severe or fatal adverse events with ramucirumab, with only modest improvements in OS or PFS.
Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.
Patients initially given pembrolizumab had longer PFS even after subsequent therapy.
A small percentage of patients with NSCLC could stand to benefit from tepotinib.
This post-hoc analysis compared efficacy of savolitinib plus osimertinib and change in EGFR ctDNA in advanced EGFR-mutant NSCLC characterized by MET amplification.
The definition of hyperprogressive disease (HPD) in advanced non–small cell lung cancer was found to vary widely, yielding “highly variable” rates of HPD.
Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.
Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.
In the 3 ongoing responses, all had PD-L1–positive disease.
